Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Q2 results

- PMLiVE

Biogen raises full year guidance after beating Q2 expectations

Key drug franchises boost total revenues in the quarter

- PMLiVE

Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales

- PMLiVE

Merck, Bayer flesh out vericiguat heart failure data at ACC

Drug reduced rate of cardiovascular deaths and hospitalisations

Bayer symbol

Bayer bulks up in women’s health again with non-hormonal contraceptive deal

If approved candidate would become a first-in-category therapy

Bayer symbol

Bayer extends alliance with Evotec in women’s health

Five-year research agreement focuses on polycystic ovary syndrome

- PMLiVE

Keytruda doesn’t extend survival in small cell lung cancer

Unlikely to extend use into the first-line setting

- PMLiVE

AZ, Merck’s Lynparza narrowly scores FDA approval for pancreatic cancer

Committee voted seven to five in favour of PARP inhibitor

- PMLiVE

Merck’s Keytruda significantly extends life in some prostate cancer patients

Pivotal study identifies group of 'super responders'

- PMLiVE

Merck acquires pre-clinical biotech Calporta for up to $576m

Expands into early-stage neurodegeneration research field

- PMLiVE

World Diabetes Day 2019

Many lack knowledge around type 2 diabetes risk factors, says new survey

- PMLiVE

Merck claims first-ever okay for Ebola vaccine, in Europe

Comes shortly after J&J filed its Ebola candidate with EMA

- PMLiVE

J&J catches up to Merck, files Ebola vaccine in Europe

Company is also in discussion with the FDA in the US to support regulatory filings

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links